Skip to content
2000
image of Dealing with Early-Onset Schizophrenia and the Role of Lurasidone: An Expert Opinion
file format pdf download PDF

Abstract

Compared to schizophrenia in adults, Early Onset Schizophrenia (EOS) features diagnostic, clinical, and therapeutic peculiarities that are the subject of ongoing discussion among psychiatrists and neuropsychiatrists. This article presents the outcomes of a meeting and a series of virtual roundtable discussions among specialists who validated practical recommendations for the diagnosis and management of EOS in light of recent literature. The identification of risk factors and prodromal symptoms, as well as the differentiation of EOS from other psychiatric conditions, is crucial for early detection. Timely identification enables the implementation of appropriate psycho-behavioural and pharmacological interventions and supports close monitoring of the developmental trajectories associated with EOS. The collaboration between the different professionals who deal with EOS patients and a therapeutic approach that allows a normal cognitive, sexual, and psychophysical development makes it possible to ensure the therapeutic alliance necessary for the optimal management of the disease over time. In a scenario that is complicated by negative prognostic factors, such as the late recognition of the disease, comorbid and latent psychiatric conditions, the increasingly widespread use of substances among adolescents, and a poor therapeutic adherence often due to antipsychotics side effects, a growing body of literature emphasizes the advantages of lurasidone in the treatment of EOS. Compared to other pharmacological agents commonly used in schizophrenia, lurasidone has been shown to intervene comprehensively and effectively against the positive and negative symptoms of EOS, with manageable side effects and the preservation of a good QoL.

© 2025 The Author(s). Published by Bentham Science Publisher.
This is an open access article published under CC BY 4.0 https://creativecommons.org/licenses/by/4.0/legalcode
Loading

Article metrics loading...

/content/journals/cn/10.2174/011570159X385722250701114931
2025-07-15
2025-10-29

  • From This Site

    /content/journals/cn/10.2174/011570159X385722250701114931
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

/deliver/fulltext/cn/10.2174/011570159X385722250701114931/BMS-CN-2025-23.html?itemId=/content/journals/cn/10.2174/011570159X385722250701114931&mimeType=html&fmt=ahah

References

  1. Solmi M. Radua J. Olivola M. Croce E. Soardo L. Salazar de Pablo G. Il Shin J. Kirkbride J.B. Jones P. Kim J.H. Kim J.Y. Carvalho A.F. Seeman M.V. Correll C.U. Fusar-Poli P. Age at onset of mental disorders worldwide: Large-scale meta-analysis of 192 epidemiological studies. Mol. Psychiatry 2022 27 1 281 295 10.1038/s41380‑021‑01161‑7 34079068
    [Google Scholar]
  2. Kendhari J. Shankar R. Young-Walker L. A review of childhood-onset schizophrenia. Focus Am. Psychiatr. Publ. 2016 14 3 328 332 10.1176/appi.focus.20160007 31975813
    [Google Scholar]
  3. Bozzatello P. Bellino S. Rocca P. Predictive factors of treatment resistance in first episode of psychosis: A systematic review. Front. Psychiatry 2019 10 67 10.3389/fpsyt.2019.00067 30863323
    [Google Scholar]
  4. Gupta N. Gupta M. Esang M. Lost in translation: Challenges in the diagnosis and treatment of early-onset schizophrenia. Cureus 2023 15 5 39488 10.7759/cureus.39488 37362509
    [Google Scholar]
  5. Horsfall J. Cleary M. Hunt G.E. Walter G. Psychosocial treatments for people with co-occurring severe mental illnesses and substance use disorders (dual diagnosis): A review of empirical evidence. Harv. Rev. Psychiatry 2009 17 1 24 34 10.1080/10673220902724599 19205964
    [Google Scholar]
  6. Driver D.I. Thomas S. Gogtay N. Rapoport J.L. Childhood-onset Schizophrenia and early-onset Schizophrenia spectrum disorders. Child Adolesc. Psychiatr. Clin. N. Am. 2020 29 1 71 90 10.1016/j.chc.2019.08.017 31708054
    [Google Scholar]
  7. Leucht S. Arango C. Lopez-Morinigo J-D. Pharmacological treatment of early-onset schizophrenia: A critical review, evidence-based clinical guidance and unmet needs. Pharmacopsychiatry 2022 55 5 233 245 10.1055/a‑1854‑0185 35777418
    [Google Scholar]
  8. Debnath M. Venkatasubramanian G. Berk M. Fetal programming of Schizophrenia: Select mechanisms. Neurosci. Biobehav. Rev. 2015 49 90 104 10.1016/j.neubiorev.2014.12.003 25496904
    [Google Scholar]
  9. Rapoport J.L. Giedd J.N. Gogtay N. Neurodevelopmental model of Schizophrenia: Update 2012. Mol. Psychiatry 2012 17 12 1228 1238 10.1038/mp.2012.23 22488257
    [Google Scholar]
  10. Pavuluri M.N. Herbener E.S. Sweeney J.A. Psychotic symptoms in pediatric bipolar disorder. J. Affect. Disord. 2004 80 1 19 28 10.1016/S0165‑0327(03)00053‑3 15094254
    [Google Scholar]
  11. Dubovsky S.L. Ghosh B.M. Serotte J.C. Cranwell V. Psychotic depression: Diagnosis, differential diagnosis, and treatment. Psychother. Psychosom. 2021 90 3 160 177 10.1159/000511348 33166960
    [Google Scholar]
  12. Okkels N. Trabjerg B. Arendt M. Pedersen C.B. Traumatic stress disorders and risk of subsequent Schizophrenia spectrum disorder or bipolar disorder: A nationwide cohort study. Schizophr. Bull. 2017 43 1 180 186 10.1093/schbul/sbw082 27245172
    [Google Scholar]
  13. Shitova A.D. Zharikova T.S. Kovaleva O.N. Luchina A.M. Aktemirov A.S. Olsufieva A.V. Sinelnikov M.Y. Pontes-Silva A. Zharikov Y.O. Tourette syndrome and obsessive-compulsive disorder: A comprehensive review of structural alterations and neurological mechanisms. Behav. Brain Res. 2023 453 114606 10.1016/j.bbr.2023.114606 37524204
    [Google Scholar]
  14. O’Connell K.S. McGregor N.W. Lochner C. Emsley R. Warnich L. The genetic architecture of Schizophrenia, bipolar disorder, obsessive-compulsive disorder and autism spectrum disorder. Mol. Cell. Neurosci. 2018 88 300 307 10.1016/j.mcn.2018.02.010 29505902
    [Google Scholar]
  15. Lenzenweger M.F. Schizotypy, schizotypic psychopathology and Schizophrenia. World Psychiatry 2018 17 1 25 26 10.1002/wps.20479 29352536
    [Google Scholar]
  16. Cederlöf M. Lichtenstein P. Larsson H. Boman M. Rück C. Landén M. Mataix-Cols D. Obsessive-compulsive disorder, psychosis, and bipolarity: A longitudinal cohort and multigenerational family study. Schizophr. Bull. 2015 41 5 1076 1083 10.1093/schbul/sbu169 25512596
    [Google Scholar]
  17. Kim H. Kim S.H. Jeong W. Park Y.S. Kim J. Park E.C. Jang S.I. Association between obsessive-compulsive disorder and the risk of Schizophrenia using the Korean National Health Insurance Service-National Sample Cohort: A retrospective cohort study. Epidemiol. Psychiatr. Sci. 2023 32 9 10.1017/S2045796023000021 36762596
    [Google Scholar]
  18. Hudak R. Rasmussen A. Obsessive-compulsive disorder and Schizophrenia: Conceptualization, assessment and cognitive behavioral treatment. J. Cogn. Psychother. 2022 36 3 247 267 10.1891/JCP‑2021‑0008 35882538
    [Google Scholar]
  19. Dines M. Kes M. Ailán D. Cetkovich-Bakmas M. Born C. Grunze H. Bipolar disorders and Schizophrenia: Discrete disorders? Front. Psychiatry 2024 15 1352250 10.3389/fpsyt.2024.1352250 38745778
    [Google Scholar]
  20. George M. Maheshwari S. Chandran S. Manohar J.S. Sathyanarayana Rao T.S. Understanding the Schizophrenia prodrome. Indian J. Psychiatry 2017 59 4 505 509 10.4103/psychiatry.IndianJPsychiatry_464_17 29497198
    [Google Scholar]
  21. Stentebjerg-Olesen M. Pagsberg A.K. Fink-Jensen A. Correll C.U. Jeppesen P. Clinical characteristics and predictors of outcome of Schizophrenia-spectrum psychosis in children and adolescents: A systematic review. J. Child Adolesc. Psychopharmacol. 2016 26 5 410 427 10.1089/cap.2015.0097 27136403
    [Google Scholar]
  22. Fusar-Poli P. Cappucciati M. Borgwardt S. Woods S.W. Addington J. Nelson B. Nieman D.H. Stahl D.R. Rutigliano G. Riecher-Rössler A. Simon A.E. Mizuno M. Lee T.Y. Kwon J.S. Lam M.M.L. Perez J. Keri S. Amminger P. Metzler S. Kawohl W. Rössler W. Lee J. Labad J. Ziermans T. An S.K. Liu C.C. Woodberry K.A. Braham A. Corcoran C. McGorry P. Yung A.R. McGuire P.K. Heterogeneity of psychosis risk within individuals at clinical high risk. JAMA Psychiatry 2016 73 2 113 120 10.1001/jamapsychiatry.2015.2324 26719911
    [Google Scholar]
  23. Lång U. Yates K. Leacy F.P. Clarke M.C. McNicholas F. Cannon M. Kelleher I. Systematic review and meta-analysis: Psychosis risk in children and adolescents with an at-risk mental state. J. Am. Acad. Child Adolesc. Psychiatry 2022 61 5 615 625 10.1016/j.jaac.2021.07.593 34363965
    [Google Scholar]
  24. Velthorst E. Fett A.K.J. Reichenberg A. Perlman G. van Os J. Bromet E.J. Kotov R. The 20-year longitudinal trajectories of social functioning in individuals with psychotic disorders. Am. J. Psychiatry 2017 174 11 1075 1085 10.1176/appi.ajp.2016.15111419 27978770
    [Google Scholar]
  25. Khokhar J.Y. Dwiel L.L. Henricks A.M. Doucette W.T. Green A.I. The link between Schizophrenia and substance use disorder: A unifying hypothesis. Schizophr. Res. 2018 194 78 85 10.1016/j.schres.2017.04.016 28416205
    [Google Scholar]
  26. Di Forti M. Quattrone D. Freeman T.P. Tripoli G. Gayer-Anderson C. Quigley H. Rodriguez V. Jongsma H.E. Ferraro L. La Cascia C. La Barbera D. Tarricone I. Berardi D. Szöke A. Arango C. Tortelli A. Velthorst E. Bernardo M. Del-Ben C.M. Menezes P.R. Selten J.P. Jones P.B. Kirkbride J.B. Rutten B.P.F. de Haan L. Sham P.C. van Os J. Lewis C.M. Lynskey M. Morgan C. Murray R.M. Amoretti S. Arrojo M. Baudin G. Beards S. Bernardo M. Bobes J. Bonetto C. Cabrera B. Carracedo A. Charpeaud T. Costas J. Cristofalo D. Cuadrado P. Díaz-Caneja C.M. Ferchiou A. Franke N. Frijda F. García Bernardo E. Garcia-Portilla P. González E. Hubbard K. Jamain S. Jiménez-López E. Leboyer M. López Montoya G. Lorente-Rovira E. Marcelino Loureiro C. Marrazzo G. Martínez C. Matteis M. Messchaart E. Moltó M.D. Nacher J. Olmeda M.S. Parellada M. González Peñas J. Pignon B. Rapado M. Richard J-R. Rodríguez Solano J.J. Roldán Díaz L. Ruggeri M. Sáiz P.A. Sánchez E. Sanjuán J. Sartorio C. Schürhoff F. Seminerio F. Shuhama R. Sideli L. Stilo S.A. Termorshuizen F. Tosato S. Tronche A-M. van Dam D. van der Ven E. The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. Lancet Psychiatry 2019 6 5 427 436 10.1016/S2215‑0366(19)30048‑3 30902669
    [Google Scholar]
  27. Daruvala R. Kumar A. Datta S.S. Do psychological interventions work for psychosis in adolescents? Schizophr. Bull. 2021 47 3 692 694 10.1093/schbul/sbaa132 32976579
    [Google Scholar]
  28. Hálfdánarson Ó. Zoëga H. Aagaard L. Bernardo M. Brandt L. Fusté A.C. Furu K. Garuoliené K. Hoffmann F. Huybrechts K.F. Kalverdijk L.J. Kawakami K. Kieler H. Kinoshita T. Litchfield M. López S.C. Machado-Alba J.E. Machado-Duque M.E. Mahesri M. Nishtala P.S. Pearson S.A. Reutfors J. Saastamoinen L.K. Sato I. Schuiling-Veninga C.C.M. Shyu Y.C. Skurtveit S. Verdoux H. Wang L.J. Yahni C.Z. Bachmann C.J. International trends in antipsychotic use: A study in 16 countries, 2005-2014. Eur. Neuropsychopharmacol. 2017 27 10 1064 1076 10.1016/j.euroneuro.2017.07.001 28755801
    [Google Scholar]
  29. Alptekin K. Kirli U. Pharmacotherapy of Schizophrenia in acute and maintenance phase. Noro Psikiyatri Arsivi 2021 58 S17 S23 10.29399/npa.27441 34658631
    [Google Scholar]
  30. Stroup T.S. Gray N. Management of common adverse effects of antipsychotic medications. World Psychiatry 2018 17 3 341 356 10.1002/wps.20567 30192094
    [Google Scholar]
  31. Remington G. Addington D. Honer W. Ismail Z. Raedler T. Teehan M. Guidelines for the pharmacotherapy of schizophrenia in adults. Can. J. Psychiatry 2017 62 9 604 616 10.1177/0706743717720448 28703015
    [Google Scholar]
  32. Bairamova S.P. Pavlova O.V. Shport S.V. Gurina O.I. Pavlov K.A. The relationship of cytochrome P450 isoforms with the efficacy and safety of antipsychotic and antidepressant therapy. Zh. Nevrol. Psikhiatr. Im. S. S. Korsakova 2023 123 11 40 46 10.17116/jnevro202312311140 37994887
    [Google Scholar]
  33. Guo J. Lv X. Liu Y. Kong L. Qu H. Yue W. Influencing factors of medication adherence in schizophrenic patients: A meta-analysis. Schizophrenia 2023 9 1 31 10.1038/s41537‑023‑00356‑x 37188714
    [Google Scholar]
  34. Correll C.U. Shi L. Weiss C. Hobart M. Eramo A. Duffy R.A. Weiller E. Baker R.A. Successful switching of patients with acute schizophrenia from another antipsychotic to brexpiprazole: comparison of clinicians’ choice of cross-titration schedules in a post hoc analysis of a randomized, double-blind, maintenance treatment study. CNS Spectr. 2019 24 5 507 517 10.1017/S1092852918001086 30306884
    [Google Scholar]
  35. Ishibashi T. Horisawa T. Tokuda K. Ishiyama T. Ogasa M. Tagashira R. Matsumoto K. Nishikawa H. Ueda Y. Toma S. Oki H. Tanno N. Saji I. Ito A. Ohno Y. Nakamura M. Pharmacological profile of lurasidone, a novel antipsychotic agent with potent 5-hydroxytryptamine 7 (5-HT7) and 5-HT1A receptor activity. J. Pharmacol. Exp. Ther. 2010 334 1 171 181 10.1124/jpet.110.167346 20404009
    [Google Scholar]
  36. Fiorillo A. Sampogna G. Albert U. Bondi E. De Giorgi S. Fagiolini A. Pompili M. Serafini G. Volpe U. Vita A. The role of lurasidone in managing depressive symptoms in people with schizophrenia: A review. Brain Sci. 2024 14 3 225 10.3390/brainsci14030225 38539614
    [Google Scholar]
  37. Riva M.A. Albert U. de Filippis S. Vita A. De Berardis D. Identification of clinical phenotypes in Schizophrenia: The role of lurasidone. Ther. Adv. Psychopharmacol. 2021 11 20451253211012250 10.1177/20451253211012250 34025981
    [Google Scholar]
  38. Loebel A. Cucchiaro J. Silva R. Mao Y. Xu J. Pikalov A. Marder S.R. Efficacy of lurasidone across five symptom dimensions of Schizophrenia: Pooled analysis of short-term, placebo-controlled studies. Eur. Psychiatry 2015 30 1 26 31 10.1016/j.eurpsy.2014.08.001 25280429
    [Google Scholar]
  39. Costamagna I. Calisti F. Cattaneo A. Hsu J. Tocco M. Pikalov A. Goldman R. Efficacy and safety of lurasidone in adolescents and young adults with Schizophrenia: A pooled post hoc analysis of double-blind, placebo-controlled 6-week studies. Eur. Psychiatry 2021 64 1 35 10.1192/j.eurpsy.2021.30 33966678
    [Google Scholar]
  40. Srisurapanont M. Suttajit S. Likhitsathian S. Maneeton B. Maneeton N. A network meta-analysis of the dose-response effects of lurasidone on acute Schizophrenia. Sci. Rep. 2021 11 1 5571 10.1038/s41598‑021‑84836‑z 33692392
    [Google Scholar]
  41. Solmi M. Fornaro M. Ostinelli E.G. Zangani C. Croatto G. Monaco F. Krinitski D. Fusar-Poli P. Correll C.U. Safety of 80 antidepressants, antipsychotics, anti‐attention‐deficit/hyperactivity medications and mood stabilizers in children and adolescents with psychiatric disorders: A large scale systematic meta‐review of 78 adverse effects. World Psychiatry 2020 19 2 214 232 10.1002/wps.20765 32394557
    [Google Scholar]
  42. Keepers G.A. Fochtmann L.J. Anzia J.M. Benjamin S. Lyness J.M. Mojtabai R. The american psychiatric association practice guideline for the treatment of patients with Schizophrenia. Am. J. Psychiatry 2020 177 9 868 872 10.1176/appi.ajp.2020.177901
    [Google Scholar]
  43. Fitzgerald H.M. Shepherd J. Bailey H. Berry M. Wright J. Chen M. Treatment goals in schizophrenia: A real-world survey of patients, psychiatrists, and caregivers in the United States, with an analysis of current treatment (long-acting injectable vs oral antipsychotics) and goal selection. Neuropsychiatr. Dis. Treat. 2021 17 3215 3228 10.2147/NDT.S330936 34707359
    [Google Scholar]
  44. Correll C.U. Findling R.L. Tocco M. Pikalov A. Deng L. Goldman R. Safety and effectiveness of lurasidone in adolescents with Schizophrenia: Results of a 2-year, open-label extension study. CNS Spectr. 2022 27 1 118 128 10.1017/S1092852920001893 33077012
    [Google Scholar]
  45. Mattingly G.W. Haddad P.M. Tocco M. Xu J. Phillips D. Pikalov A. Loebel A. Switching to Lurasidone following 12 months of treatment with Risperidone: Results of a 6-month, open-label study. BMC Psychiatry 2020 20 1 199 10.1186/s12888‑020‑02523‑1 32370778
    [Google Scholar]
  46. Fagiolini A. Olivola M. Lavatelli L. Bellomo A. Lobaccaro C. Falsetto N. Micillo M. Cuomo A. Treatment persistence in patients with Schizophrenia treated with lurasidone in Italian clinical practice. Ann. Gen. Psychiatry 2022 21 1 49 10.1186/s12991‑022‑00425‑y 36527022
    [Google Scholar]
  47. Storman D. Koperny M. Styczeñ K. Datka W. Jaeschke R.R. Lurasidone versus typical antipsychotics for Schizophrenia. Cochrane Libr. 2025 2025 1 CD012429 10.1002/14651858.CD012429.pub2 39831535
    [Google Scholar]
  48. Azhar Y. Shaban K. Lurasidone. StatPearls. Treasure Island, FL StatPearls Publishing 2025
    [Google Scholar]
  49. Yoshikawa A. Li J. Alliey-Rodriguez N. Meltzer H.Y. Genetic markers of early response to lurasidone in acute Schizophrenia. Pharmacogenomics J. 2025 25 1-2 3 10.1038/s41397‑024‑00360‑z 39979276
    [Google Scholar]
  50. De Filippis S. Vita A. Cuomo A. Amici E. Giovanetti V. Lombardozzi G. Pardossi S. Altieri L. Cicale A. Dosoli M. Galluzzo A. Invernizzi E. Rodigari P. Mascagni P. Santini C. Falsetto N. Manes M.A. Micillo M. Fagiolini A. Treatment satisfaction and effectiveness of Lurasidone on quality of life and functioning in adult patients with Schizophrenia in the real-world Italian clinical practice: A prospective 3-month observational study. Ann. Gen. Psychiatry 2024 23 1 43 10.1186/s12991‑024‑00531‑z 39501351
    [Google Scholar]
  51. Takeuchi H. Uchida H. Efficacy and safety of dose increase from 40 mg/d to 80 mg/d of lurasidone in patients with Schizophrenia: A post hoc analysis of extension trial. J. Clin. Psychopharmacol. 2025 45 1 16 19 10.1097/JCP.0000000000001943
    [Google Scholar]
  52. Liu Q. Wu Q. Yu X. Safety and efficacy of different initial doses of lurasidone in the treatment of Schizophrenia: A randomized, open-label, multi-center study. Int. J. Neuropsychopharmacol. 2025 28 Suppl. 1 i158 10.1093/ijnp/pyae059.273
    [Google Scholar]
  53. Miura I. Horikoshi S. Ichinose M. Suzuki Y. Watanabe K. Lurasidone for the treatment of schizophrenia: Design, development, and place in therapy. Drug Des. Devel. Ther. 2023 17 3023 3031 10.2147/DDDT.S366769 37789971
    [Google Scholar]
  54. Mora F. Gómez Sánchez-Lafuente C. De Iceta M. Roset C. Cárdenas A. Pérez D. Álvarez-Barón E. Gabarda-Inat I. Lurasidone uses and dosages in Spain: RETROLUR, a real-world retrospective analysis using artificial intelligence. Front. Psychiatry 2025 15 1506142 10.3389/fpsyt.2024.1506142 40013022
    [Google Scholar]
  55. Gelman A. Jacobsohn T. Yi H. Pinkhasov A. Lurasidone-induced tardive dyskinesia reversed with lithium therapy: A case report. J. Pharm. Pract. 2025 10.1177/08971900251326824 40085813
    [Google Scholar]
  56. Begni V. Silipo D.M. Bottanelli C. Papp M. Cattaneo A. Riva M.A. Chronic treatment with the antipsychotic lurasidone modulates the neuroinflammatory changes associated with the vulnerability to chronic mild stress exposure in female rats. Brain Behav. Immun. 2025 123 586 596 10.1016/j.bbi.2024.10.001 39384053
    [Google Scholar]
  57. Ekinci R. Uygun S. Mechanism of action and uses of lurasidone, a new generation of antipsychotics: A review. Psychiatry Behav. Sci. 2025 15 1 25 35 10.5455/PBS.20241104052122
    [Google Scholar]
  58. Carmellini P. Cuomo A. Vignapiano A. Monaco F. Pardossi S. Firenzuoli B. Fagiolini A. Presence of psychotic spectrum symptoms before age 12 in Schizophrenia patients: A retrospective study on clinical implications for early detection and intervention. Brain Sci. 2025 15 3 311 10.3390/brainsci15030311 40149832
    [Google Scholar]
  59. Pontillo M. Averna R. Tata M.C. Chieppa F. Pucciarini M.L. Vicari S. Neurodevelopmental trajectories and clinical profiles in a sample of children and adolescents with early- and very-early-onset schizophrenia. Front. Psychiatry 2021 12 662093 10.3389/fpsyt.2021.662093 34603093
    [Google Scholar]
  60. Vita A. Barlati S. Bellomo A. Poli P.F. Masi G. Nobili L. Serafini G. Zuddas A. Vicari S. Patterns of care for adolescent with Schizophrenia: A delphi-based consensus study. Front. Psychiatry 2022 13 844098 10.3389/fpsyt.2022.844098 35432022
    [Google Scholar]
  61. Vita A. Barlati S. Porcellana M. Sala E. Lisoni J. Brogonzoli L. Percudani M.E. Iardino R. The patient journey project in Italian mental health services: results from a co-designed survey on clinical interventions and current barriers to improve the care of people living with Schizophrenia. Front. Psychiatry 2024 15 1382326 10.3389/fpsyt.2024.1382326 38606407
    [Google Scholar]
  62. Scott J.G. Annual research review: Psychosis in children and adolescents - A call to action: A commentary on Kelleher (2025). J. Child Psychol. Psychiatry 2025 66 4 588 591 10.1111/jcpp.14135 40017173
    [Google Scholar]
  63. Armita A. Guivarch J. Dor E. Laure G. Zeghari R. Gindt M. Thümmler S. Askenazy F. Fernandez A. Neurocognitive dysfunctions in childhood-onset Schizophrenia: A systematic review. Schizophr. Res. Cogn. 2025 40 100342 10.1016/j.scog.2024.100342 39867751
    [Google Scholar]
  64. Cheng P. Liu Z. Wang F. Yang J. Yang J. Dynamic functional connectome configurations underlying working memory deficits in adolescents with early-onset Schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2025 137 111303 10.1016/j.pnpbp.2025.111303 40015619
    [Google Scholar]
  65. Salazar de Pablo G. Catalan A. Vaquerizo Serrano J. Pedruzo B. Alameda L. Sandroni V. Armendariz A. Rodriguez V. Arango C. Moreno C. Downs J. Abbott C. Shin J.I. Solmi M. Fusar-Poli P. Correll C.U. Negative symptoms in children and adolescents with early-onset psychosis and at clinical high-risk for psychosis: Systematic review and meta-analysis. Br. J. Psychiatry 2023 223 1 282 294 10.1192/bjp.2022.203 37194556
    [Google Scholar]
  66. Iftimovici A. Martinez G. Victor J. Bendjemaa N. Jantac C. Danset-Alexandre C. Amado I. Pina-Camacho L. Chaumette B. Fatjó-Vilas M. Fañanás L. Duchesnay E. Krebs M.O. Schizophrenia following early adolescence prodrome: A neurodevelopmental subtype with autism-like sensorimotor and social cognition deficits. Schizophr. Bull. 2025 2025 sbae202 Epub ahead of print 10.1093/schbul/sbae202 39756426
    [Google Scholar]
  67. Kelleher I. Annual research review: Psychosis in children and adolescents: Key updates from the past 2 decades on psychotic disorders, psychotic experiences, and psychosis risk. J. Child Psychol. Psychiatry 2025 66 4 460 476 10.1111/jcpp.14088 39754377
    [Google Scholar]
/content/journals/cn/10.2174/011570159X385722250701114931
Loading

  • Article Type:     Research Article
Keywords: adolescence psychosis ; EOS management ; psychiatric conditions ; lurasidone ; antipsychotic drugs ; Early Onset Schizophrenia EOS

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test